The FDA Did Not Approve Six Peptides: What the July 2026 Compounding Vote Actually Was

On 23 and 24 July 2026, a federal advisory committee sitting at the FDA’s White Oak campus in Maryland spent two days voting on seven peptides. By the weekend a large share of the internet had concluded that the FDA had approved them. It had not. What actually happened was narrower, more procedural, and considerably more interesting than the headlines suggested. Condor Research supplies materials for laboratory research only; nothing described below changes that, and nothing below concerns use in humans.

We wrote a preview of this meeting before it took place, setting out what was on the agenda and what the committee could and could not decide — see our preview of the July 2026 FDA peptide review. This piece is the outcome.

What did the committee actually vote on?

The body that met was the Pharmacy Compounding Advisory Committee (PCAC), a standing FDA advisory panel.¹ Its question was not whether these peptides work, and not whether they should be sold. It was whether each substance should be recommended for inclusion on the Section 503A Bulk Drug Substances list — the so-called bulks list — which governs what state-licensed pharmacies and physicians in the United States may use as a starting material when compounding a medicine for a named patient.

Seven peptides were on the agenda, each paired with a specific indication that FDA’s reviewers had evaluated. The free-base and acetate forms of each compound were voted on separately; in every case the two tallies matched. The public docket for the proceeding, No. FDA-2025-N-6895, drew more than 1,800 comments.²

How did the seven peptides fare?

Tallies as reported by trade and health press;³⁴ FDA had not published an official tally sheet at the time of writing, so this table is provisional pending the agency’s official transcript. Reported totals differ between outlets for Epitalon, and the number of votes cast varied between sessions. The indications listed are the uses FDA’s reviewers assessed, not permitted uses, not recommendations, and not claims. Nothing here authorises human use of any compound, and all materials referenced remain Research Use Only.

Why did the committee overrule its own scientists?

This is the part the headlines mostly skipped. FDA’s Center for Drug Evaluation and Research assembled scientific review packages for each of the seven substances, and the review team recommended against listing all seven.⁴ The reasons were consistent across the set: a near-total absence of human clinical data, an evidence base resting on animal models and in-vitro work, and unresolved safety questions including immunogenicity and, for at least one compound, concerns about tumour promotion.

For TB-500 the gap was starker still. FDA acknowledged during the proceedings that there are no studies on TB-500 itself — the literature commonly cited for it concerns related material, not the substance under consideration.⁶ The committee recommended it anyway, 8-6-1. Reporters in the room described an audible gasp after the BPC-157 tally was read.⁵

0 peptides were approved as medicines. The committee was never asked whether any of them work.

What does a 503A listing actually permit?

Section 503A of the US Food, Drug, and Cosmetic Act creates a carve-out.⁷ A state-licensed pharmacist or physician who compounds a drug for an individually identified patient, pursuant to a valid prescription, is exempt from three otherwise universal requirements: new-drug approval, current good manufacturing practice, and adequate directions for use. That exemption is conditional. Among the conditions is that the bulk substance used must be a component of an FDA-approved drug, must have a United States Pharmacopeia or National Formulary monograph, or must appear on the 503A bulks list.

So a listing opens a regulated prescription-compounding channel inside the United States, for one patient at a time, on a prescriber’s judgement. It is not drug approval. It does not authorise retail sale. It does not authorise marketing, advertising or general distribution. And it carries no finding whatsoever that the compound is effective for anything.

A vote to add a substance to a compounding list is not a finding that it works. It is a finding about who may prepare it, for whom, and under what conditions.

What has to happen before anything changes?

The committee’s advice is exactly that: advisory, and non-binding. FDA must now review the meeting record and the public docket, then run formal notice-and-comment rulemaking under 21 CFR 216.23 — a proposed rule, a comment period, and a final rule.⁷ Attorneys at Frier Levitt assessed that this sequence is unlikely to conclude before 2027 or 2028.⁸ FDA generally follows PCAC advice, but it is not obliged to, and it has decided against the committee before.⁶

~10 substances have completed the full 503A listing process since Congress created the list in 1997.

A second PCAC meeting is scheduled to take place before the end of February 2027. Its agenda covers cathelicidin (LL-37), GHK-Cu, dihexa acetate, Melanotan II and pegylated mechano growth factor (PEG-MGF).⁹

How did these compounds reach the agenda at all?

In 2023, FDA placed 19 peptides in 503A Category 2 — substances that raise significant safety risks.¹⁰ In February 2026, HHS Secretary Robert F. Kennedy Jr., who oversees FDA and has publicly supported easing restrictions on peptides, announced that roughly 14 of them would be reclassified.¹¹ Between around 15 and 23 April 2026, FDA removed 12 peptides from Category 2 on the basis that their nominations had been withdrawn, and removed GHK-Cu from Category 1.¹²

The nuance matters and was widely lost. Removal from Category 2 is not authorisation. FDA’s enforcement discretion attaches to affirmative Category 1 status or to inclusion on the bulks list, so a compound that is simply no longer in Category 2 sits in a gray zone rather than a permitted one.⁹ That was the status of most of these substances going into the July meeting, and it is a large part of why the meeting mattered — see our explainer on the peptide gray market.

Who objected, and on what grounds?

TIME reported that many of the voting members consult with or are employed by companies positioned to promote or dispense peptides, a departure from the academic and research composition these panels usually have.¹³ Peter Lurie, a former FDA associate commissioner who now leads the Center for Science in the Public Interest, testified that allowing peptides to be compounded “removes incentives to go through FDA’s rigorous drug approval process”.¹³ Public Citizen and the Partnership for Safe Medicines also opposed listing. Adrienne Fugh-Berman of Georgetown described MOTS-c as a poorly characterised experimental drug and argued that commercial interest in a substance is a reason to study it, not a reason to legalise it.⁶

The commercial backdrop was not subtle. Analysts put the telehealth opportunity around $2.2 billion, and Hims & Hers stock rose more than 10% after the BPC-157 vote.¹³ Supporters of listing made a different argument, and it is not a frivolous one: these compounds are already circulating in an unregulated market, and a supervised 503A pathway with a licensed prescriber, a named patient and a traceable compounding pharmacy is safer than what exists now.¹⁴

What the FDA actually approved that same week

For contrast, here is what a genuine FDA approval looked like during the same seven days. Each of the following is a marketing authorisation for a specific product, reviewed against a submitted evidence package.

These are approvals. The peptide votes were not. This table is included solely to illustrate the difference between an FDA marketing authorisation and a non-binding advisory recommendation about a compounding list, and implies nothing about the availability, legality or suitability of any research compound.

The Jideytro clearance rested on ARROS-1, a single-arm phase I/II trial in 117 patients, with an objective response rate of 44% (95% CI 34-53) and duration-of-response rates of 82% at six months and 69% at twelve.¹⁵ Modest by the standards of a randomised trial, and vastly more than exists for any of the seven peptides.

The sharpest comparison came a week earlier. On 16 July, FDA approved Lipfendra (enlicitide), Merck’s first oral PCSK9 inhibitor — and a macrocyclic peptide. The CORALreef phase 3 programme reported LDL-C reductions of 56% versus placebo at week 24 in CORALreef Lipids and 59% in CORALreef HeFH.²⁰ That is what a peptide drug looks like when it goes through the full process.

An honest read of what this changes

Two things are true at once, and the temptation is to pick one.

The first: a committee overruled its own agency’s scientific reviewers on seven compounds for which the human evidence ranges from thin to absent, and in one case is absent for the specific substance under discussion. That is a real thing to be uncomfortable about, whatever one thinks of FDA generally. A vote does not create data. Six recommendations do not make BPC-157 better characterised on Friday than it was on Wednesday, and the panel was never asked to make that finding.

The second: the counterfactual is not a world in which nobody encounters these compounds. It is the current one, in which they move through unregulated channels with no prescriber, no pharmacy oversight and no traceability. A 503A pathway is a narrower and more accountable channel than that. People who have watched the grey market up close are not being unreasonable when they say so.

Neither observation cancels the other, and the honest position is to hold both. What should be resisted is the framing that appeared almost immediately: that a regulatory door has opened, that these compounds are on their way to legitimacy, and that the sensible response is to move early. None of that follows. The vote is advisory, the rulemaking has not started, the timeline runs to 2027 or 2028 at the earliest, roughly ten substances have made it through since 1997, and FDA’s own scientists are on record against all seven.

It also bears repeating that this is a United States process, and only that. It concerns US compounding pharmacies operating under US federal law. It has no bearing on EU or UK medicines regulation, on national controls, or on how any of these compounds is classified in any European jurisdiction — see the legal status of research compounds in Europe.

Nothing in this vote changes what Condor Research supplies or how. Every material in our catalogue is offered strictly for laboratory research use, is not a medicine, is not for human or veterinary use, and is not for diagnostic or therapeutic application — a regulatory recommendation about US prescription compounding does not alter any part of that, and we are not treating it as though it does. If the framework itself is unfamiliar, what Research Use Only actually means sets it out. We will update this piece when FDA publishes the official meeting record, and again if and when a proposed rule appears.

Condor Research · Scientific desk
Atrio Sciences s.r.o., IČO 57 669 651, Nitra (SK) · info@condorresearch.com